Psychedelic-assisted therapy

Psychedelic-assisted therapy treats the psychedelic experience not as an incidental side effect of medication but as the central event of a therapeutic process. Its distinctive method—often a single high-dose session, carefully prepared and supported—challenged psychiatry’s established models of illness and treatment. It also unsettles a simple division between medicine and spirituality: the drug, the therapist, the participant’s expectations, and the setting all help shape what happens and what it may mean.

A different therapeutic model

In the mid-1950s, Humphry Osmond, Al Hubbard, and Aldous Huxley advanced a model that departed sharply from two more familiar ways of explaining psychedelic drugs. Psychotomimetic theories treated their effects as resembling psychosis, making them legible within conventional psychiatry. Psycholytic approaches incorporated drugs into psychoanalysis as an aid to talking therapy. Psychedelic therapy proposed something more disruptive: a high-dose session intended to occasion a conversion-like experience, potentially replacing a long course of weekly sessions with a concentrated encounter. The change implied new roles for both patient and therapist, not simply a new medication added to an unchanged treatment plan.

The model’s spiritual associations heightened institutional unease. Charles Grob later characterized it as applied mysticism, pointing to its blurring of boundaries between religion and science, sickness and health, and healer and sufferer. Its attention to set and setting—the participant’s state of mind and the conditions surrounding the session—also meant that treatment could not be reduced to a drug acting in isolation. The therapist was not merely prescribing a substance; the therapist helped organize the circumstances in which a powerful and potentially suggestive experience unfolded.

A treatment made of more than a drug

That dependence on context creates a methodological problem for clinical research. Participants and guides can often tell whether a session involved psilocybin or a placebo, making conventional blinding difficult. Researchers must also reckon with the influence of the setting, the therapeutic relationship, and the participant’s expectations. Those factors complicate efforts to isolate a chemical effect from the experience built around it. The deeper question is how medicine should evaluate a treatment whose apparent action may include the meanings a person forms during an altered state, rather than a strictly pharmacological effect alone.

Charles Grob argued that rigorous scientific methods would not be enough by themselves: researchers should also consider what successful applications of the shamanic paradigm can teach about deliberately shaping the conditions of a session. This does not make the clinical and spiritual accounts identical. It does locate psychedelic therapy on a contested frontier where therapeutic structure, suggestibility, and meaning are inseparable questions. The scientific challenge is not merely to measure a molecule, but to study a treatment in which context may be one of its active ingredients.

Guides, safeguards, and an underground lineage

After sanctioned psychedelic therapy ended, practice continued in an underground network that the book distinguishes from the broader illegal market in psychedelic drugs. The network included perhaps a couple hundred guides and therapists who used substances in carefully prescribed ways, aiming to treat illness or support spiritual, creative, or emotional development. Its practitioners included credentialed therapists, religious professionals, people describing themselves as shamans, and practitioners trained in a range of alternative approaches. Some risked their freedom and professional licenses by continuing the work.

The guides interviewed by the author were generally open and trusting, but the work remained illegal, and participants asked that their names, locations, and other identifying details be changed. The author emphasizes that the people described were real individuals, not composites. Most guides could trace a professional lineage to therapists active when psychedelic work was legal, often through Timothy Leary, Stanislav Grof, Al Hubbard, or Leo Zeff. Zeff, who died in 1988, said he had processed three thousand patients and trained 150 guides. His account, first published anonymously as The Secret Chief and later republished with his identity disclosed, presents a practitioner who seemed more like a folksy family friend than a renegade or mystic, despite occupying both roles in the underground tradition.

That tradition developed practical safeguards rather than relying on the authority of individual guides alone. A collaboratively maintained website offered forms for legal releases, ethical agreements, and medical questionnaires, as well as a draft charter supporting wider access to profound experiences. Its Code of Ethics for Spiritual Guides recognized that participants may be unusually open to suggestion and exploitation. It called on guides to disclose risks, obtain consent, preserve confidentiality, protect participants’ health and safety, restrain self-promotion, and accommodate clients regardless of their ability to pay. The Guidelines for Voyagers and Guides gathered advice on preparation, drug interactions, intention, the course of a session, frightening material, and post-session integration. Together, these documents made the practice resemble a profession with shared protocols, even without the formal protections of a legal clinical institution.

Clinical practice and the therapist’s role

A clinical session described in the book shows how those principles could be translated into a structured treatment path. Patrick Mettes entered a trial after completing forms and answering screening questions. His wife, Lisa Callaghan, opposed the idea because she did not want an easy way out and wanted him to keep fighting. Patrick nevertheless enrolled and was assigned to Tony Bossis; the two established an immediate rapport. After three or four preparatory talking sessions, Patrick was scheduled for two dosing days: one with a high dose of niacin as an active placebo, and another with 25 milligrams of psilocybin.

For each session, Patrick would spend most of the day lying on a couch with eyeshades and headphones, listening to a curated playlist that included Brian Eno, Philip Glass, Pat Metheny, Ravi Shankar, classical music, and New Age compositions. Bossis and a second sitter, Krystallia Kalliontzi, would remain present, speaking little but available if he needed help. Patrick received flight instructions written by Bill Richards. Bossis urged him to trust the process and to approach frightening material rather than flee from it. The arrangement made the therapist’s role concrete: preparation, music, the presence of sitters, and guidance during difficult moments formed part of the treatment rather than decorative surroundings.

A later New York University follow-up study, led in part by Alexander Belser, shifted attention from mystical experience alone toward psychotherapy and patients’ accounts of change. Interviewed participants described stronger connection to loved ones and a movement from separateness toward interconnectedness, often accompanied by joy, bliss, or love. Difficult stretches could give way to surrender and acceptance, including acceptance of cancer. Coauthor Jeffrey Guss interpreted these effects as egolytic: when the usual boundaries between conscious and unconscious, or self and other, loosen, patients may become less confined by rigid thought and more able to perceive new meanings. The findings place the therapist and the participant’s relationships inside the explanation of change, not outside it.

Experience, meaning, and the limits of explanation

The account does not claim that spiritual language settles the question of how psychedelic therapy works. Loss of self may be approached psychologically or neurobiologically, including through research on disruption of the default mode network. A sense of sacredness may also be described in secular terms as heightened meaning or purpose. These vocabularies offer different angles on experience; none is presented as having the final word.

Meaning may arise through several interacting processes. Research discussed in the book suggests that changes in brain connectivity could accompany new perspectives, while an LSD music experiment found that volunteers could attach marked, lasting personal significance to songs that had previously meant little to them. Suggestibility and a therapist’s preparation may also influence interpretation. Guss told patients that the medicine might reveal unknown parts of themselves and help them understand life and existence, while leaving room for a mystical or transcendent experience without defining it in advance. The same therapeutic encounter can therefore be described as clinical insight, personal meaning-making, or spiritual discovery, depending on the language brought to it.

For people facing death, the possibility of renewed purpose may matter even when its source remains uncertain. The book presents psychedelic therapy as potentially helping participants situate the self within a wider context—through connection, nature, or universal love—and thereby make extinction somewhat easier to contemplate. That is a claim about a possible therapeutic contribution, not proof that the experience removes suffering or resolves the metaphysical question of what follows death. The model’s importance lies partly in refusing to treat such meaning as irrelevant to care, while its risks and suggestibility make preparation, ethical responsibility, and integration indispensable.